PPT-REPORTING SERIOUS ADVERSE

Author : carny | Published Date : 2023-11-19

EVENTS AND COMPLETING THE REPORT FORM Trial protocol code ISRCTN30952488 Version 2 21 Nov 2017 USE THIS PRESENTATION WITH The Trial Protocol Section 29 and

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "REPORTING SERIOUS ADVERSE" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

REPORTING SERIOUS ADVERSE: Transcript


EVENTS AND COMPLETING THE REPORT FORM Trial protocol code ISRCTN30952488 Version 2 21 Nov 2017 USE THIS PRESENTATION WITH The Trial Protocol Section 29 and G uidance for investigators . OBJECTIVES. Describe Adverse Events, Risks and Problems that can Occur in . H. uman . S. ubjects . R. esearch . C. ompliance with Safety . R. eporting . R. egulations in Clinical Research. Identify Current Systems of Patient Care and Patient Safety in Research. . May 21, 2012 – Call 1 of 2. Sponsoring Offices:. National Center for Ethics in Health Care . Office of Quality, Safety and Value, Risk Management Program. Welcome. Materials from this call as well as the call from August 6, 2012 (Critical Thinking About Institutional Disclosure of Adverse Events to Patients) are available on these websites:. Zarif Jabbar-Lopez, MBBS, MPH. FY2, East of England Deanery. Visiting Research Fellow, Uppsala Monitoring Centre. Disclosure. No conflicts of interest. The . research leading to these results was conducted as part of the PROTECT consortium (. Presentation to HL7 Patient Care WG . Draft Recommendations for Canadian Standards (being discussed). NB: HL7 . meeting discussion notes are included on slide 21. . Post meeting notes from . Russell B. Leftwich, M.D.,  . Rachel Phillips & Victoria Cornelius. Review. “recommended improvements in the accuracy of harm data in RCT reports and a need to standardize practices for reporting.”. Review. “found that methods used to collect adverse event data, the frequency of collection, and the selection criteria used by authors for reporting adverse events vary substantially, and these events are often inadequately reported.”. Holden Comprehensive Cancer Center. Protocol Development and Monitoring . Key definitions. Identifying, documenting and reporting Adverse Events. Investigator Responsibilities . How are research participants protected? . Adverse Childhood Experience’s (ACE ) Implications for the classroom Adapted from: Stewart, Altha J. University of Tennessee Health Science Center. March 7, 2016 Agenda Introduction Objective: Participants Clinical and Institutional Disclosure of Adverse Events to Patients Call 1 of 2 Delivered May 21, 2012 updated to reflect directive’s reissue (October 31, 2018) Sponsoring Offices: National Center for Ethics in Health Care MODULE 3 Adverse events following immunizationOverviewUnder recommended conditions all vaccines used in national immunization programmes are safe and e31ective if used correctly In practice however no 2019 Spring. SAFETY of the SUBJECT. Safety of the Subject. Key definitions. Identifying, documenting and reporting. Investigator reporting responsibilities . How are research participants protected? . Reporting and Management. Dr Vikas Madaan,. Senior Programme Manager. AEFI Secretariat, ITSU. Basics of AEFI surveillance. Definition. Types and categories of AEFI. AEFI organization. Reporting and Timeliness. Yousef Ahmed . Alomi. , . Nouf. Hassan . Alamoudi. , . Sabah . Alanazi. , . Abeer. . Hussin. . Almasoudi. ABSTRACT: . Objective: . . To state the physicians and dentists’ knowledge and responsiveness of the adverse drug reaction (ADR) and reporting system in Saudi Arabia. . Investigator Kick-off Meeting. January 30-31, Clearwater, Florida. Jodie Riley, MISM and Robert Silbergleit. Adverse Events. Adverse Events (AEs) are “. . . any . untoward. medical occurrence in a subject that was not previously identified which does not necessarily have a causal relationship to the study drug…” . Authors: . 1. Juliet Jokwiro, . 1. Nicole Chekudambune-Kawaza, . 1. Kenny Sithole, . 1. Bongani Dube, . 2. Charles Sandy, . 2. Manners Ncube, . 2 . Regina Mubau,. 2. Chlorata Gwanzura, . 2. Kwenziweyinkosi Ndlovu, .

Download Document

Here is the link to download the presentation.
"REPORTING SERIOUS ADVERSE"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents